Healthcare
Coloplast A/S Class B(CLPBF)
Live Price
Offline$57.00
+0.33% today
1Y Change
-36.61%
Window
Jun 25, 2025 β Jun 24, 2026
- Market Cap
- $91.16B
- Revenue Growth
- +2.9%
- EPS Growth
- -28.3%
- Dividend Yield
- 5.7%
Coverage: 250 bars Β· Jun 25, 2025 β Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Coloplast A/S Class B (CLPBF) is a Healthcare stock with a market cap of $91.16B and listed on OTC. The stock last traded around $57.00 and down 36.6% across the available one-year price window (Jun 25, 2025 β Jun 24, 2026). Baseline metrics include revenue growth of +2.9%, EPS growth of -28.3%, a dividend yield of 5.7%. What stands out right now is revenue +2.9%, EPS -28.3%, free cash flow +275.3% with operating margin 27.0% and ROIC 10.9%. The dividend matters to the case here, with a current yield around 5.7%. Valuation is more restrained than many high-expectation growth names at P/E 22.8 and price/sales 3.3. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines CLPBF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+2.9% vs +7.6% peer median
Operating Margin
Above sector median
+27.0% vs +19.4% peer median
P/E
Below sector median
22.8 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 12, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +2.9% and EPS is at -28.3%, with operating margin around 27.0%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 5.7%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -2.0% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 12, 2026 | β | +2.1% | -2.2% | -9.0% |
2026 Feb 6, 2026 | +3.5% | -5.3% | -5.3% | -12.6% |
2025 Aug 19, 2025 | -32.3% | +4.4% | +1.7% | +2.1% |
Benchmark Edge
CLPBF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CLPBF
β
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CLPBF Max Drawdown
-42.37%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CLPBF and SPY.
Company Overview
Coloplast A/S Class B
OTC
Coloplast A/S Class B is the Class B share of a leading Danish medical device company specializing in intimate healthcare solutions. Founded in 1954 and headquartered in Humlebæk, Denmark, it develops, manufactures, and markets products for ostomy care, continence care, voice and respiratory care, interventional urology, advanced wound dressings, and biologics. Key offerings include ostomy systems like SenSura Mio for customized fit and discretion, intermittent catheters, penile implants, slings for incontinence, and wound care products for chronic conditions. The company serves patients via hospitals, institutions, wholesalers, and pharmacies, with over 60% of sales from Europe, followed by other developed markets and emerging regions. Employing around 16,000 to 17,000 people, Coloplast holds a strong position in the healthcare equipment sector, focusing on chronic care needs and demonstrating consistent operational performance through its global reach and specialized portfolio.
- Leadership
- Mr. Kristian Villumsen
- Employees
- 16.6k
- Street Address
- Holtedam 1-3
- Mailing
- Humlebæk, 3050
- Region
- Humlebæk, Denmark
- Last Updated
- May 8, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 22.8
- EV/EBITDA
- 13.9
- Price/Sales
- 3.3
- Price/Book
- 6.6
Growth
- Revenue
- +2.9%
- EPS
- -28.3%
- Free Cash Flow
- +275.3%
Profitability
- Gross Margin
- 65.0%
- Operating Margin
- 27.0%
- Net Margin
- 14.3%
- ROE
- 25.2%
- ROIC
- 10.9%
Balance Sheet
- Debt/Equity
- 1.87
- Current Ratio
- 1.30
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.